Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program
Recruiting now
Conditions studied: Aneurysmal Subarachnoid Hemorrhage
In brief
Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening cerebrovascular emergency with high mortality and disability rates. Despite advances in neuroimaging and interventional techniques, outcomes remain poor for many patients due to complex post-rupture complications such as delayed cerebral ischemia (DCI), pneumonia, and other systemic injuries. These secondary events critically affect neurological recovery, yet their molecular mechanisms are not fully understood. This multicenter study aims to investigate the biological basis of post-rupture complications and prognosis in patients with aSAH through integrated multi-omics and clinical data analysis. Biospecimens including blood, cerebrospinal fluid, urine, and other relevant tissues will be collected for genomic, transcriptomic, proteomic, metabolomic, and imaging-omic profiling. By linking molecular data with clinical and imaging indicators, the study seeks to identify key pathways and biomarkers associated with secondary injury and outcome heterogeneity.
Key facts
- Study ID
- NCT07270419
- Run by
- Xiaolin Chen, MD
- People needed
- 2000
- Starts
- 2023-11-01
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2025-12-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Adult patients aged ≥18 years;
- Confirmed diagnosis of aneurysmal subarachnoid hemorrhage (aSAH) by CTA, or DSA;
- Aneurysm secured by either microsurgical clipping or endovascular coiling during hospitalization;
- Time from onset to aneurysm treatment ≤ 72 hours;
- Availability of biospecimens, including blood, cerebrospinal fluid (CSF), urine, or fecal samples collected during hospitalization;
- Signed informed consent obtained from the patient or legal representative.
You may not qualify if…
- History of previous intracranial aneurysm surgery or embolization;
- Non-aneurysmal SAH, traumatic SAH, or perimesencephalic non-aneurysmal hemorrhage;
- Presence of malignancy, severe hepatic or renal dysfunction, or other systemic diseases that may affect survival or biomarker expression;
- Severe cardiorespiratory insufficiency or unstable medical condition precluding study participation;
- Pregnancy or lactation;
- Refusal to participate or withdrawal of consent.
Where it is running
- Beijing Tiantan Hospital — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.